ArticleCell death and differentiation2017
Double-stranded RNA promotes CTL-independent tumor cytolysis mediated by CD11b
Article in Cell death and differentiation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Intratumoral pro-oxidants promote cancer immunotherapy by recruiting and reprogramming neutrophils to eliminate tumors.Cancer immunology, immunotherapy : CII · 2023Pooled it
- Microbiota in cancer: current understandings and future perspectives.Signal transduction and targeted therapy · 2026Review
- Myeloid-derived suppressor cells and their subsets serve as potential biomarkers for the progression of brucellosis.Frontiers in microbiology · 2026Article
- Neutrophils in cancer: from immune defense to tumor promotion.Cancer biology & medicine · 2025Review
- Seasonal influenza vaccines differentially activate and modulate toll-like receptor expression within the tumor microenvironment.Frontiers in oncology · 2024Article
- Toll‑like receptor 3 ligands for breast cancer therapies (Review).Molecular and clinical oncology · 2023Review
- "Open Sesame" to the complexity of pattern recognition receptors of myeloid-derived suppressor cells in cancer.Frontiers in immunology · 2023Review
- Combining Photodynamic Therapy with Immunostimulatory Nanoparticles Elicits Effective Anti-Tumor Immune Responses in Preclinical Murine Models.Pharmaceutics · 2021Article
- Dual roles of myeloid-derived suppressor cells induced by Toll-like receptor signaling in cancer.Oncology letters · 2021Review
- Review
- Gene signature for prediction of radiosensitivity in human papillomavirus-negative head and neck squamous cell carcinoma.Radiation oncology journal · 2020Article
- Gentamicin Induced Microbiome Adaptations Associate With Increased BCAA Levels and Enhance Severity of Influenza Infection.Frontiers in immunology · 2020Article
- AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells.Cancer research · 2019Article
- CXCR2 expression on granulocyte and macrophage progenitors under tumor conditions contributes to mo-MDSC generation via SAP18/ERK/STAT3.Cell death & disease · 2019Article
- Combined Adjuvant of Poly I:C Improves Antitumor Effects of CAR-T Cells.Frontiers in oncology · 2019Article
- Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression.Frontiers in immunology · 2018Review
- The TLR3/TICAM-1 signal constitutively controls spontaneous polyposis through suppression of c-Myc in ApcJournal of biomedical science · 2017Article
- Role of poly(ε-caprolactone) lipid-core nanocapsules on melanoma-neutrophil crosstalk.International journal of nanomedicine · 2017Article
- Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy.Frontiers in immunology · 2017Review
- Synergy of purine-scaffold TLR7 agonist with doxorubicin on systemic inhibition of lymphoma in mouse model.Journal of Cancer · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PolyI:C, a synthetic double-stranded RNA analog, acts as an immune-enhancing adjuvant that regresses tumors in cytotoxic T lymphocyte (CTL)-dependent and CTL-independent manner, the latter of which remains largely unknown. Tumors contain CD11b
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.